Active	Status	Sponsor type	Region	Phase	Filter
8 Active 0 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Sadiq, Ahad
PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors	Active, not recruiting	3	600	Europe, Canada, US, RoW	Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere	OncoC4, Inc., BioNTech SE	Non Small Cell Lung Cancer	06/26	06/27
KICKSTART, NCT04622007: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC Jan 2024 - Mar 2024 : Q1'24 - Data from P2b KICKSTARTtrial in combination with Keytruda for PD-L1+ve 1L NSCLC	Active, not recruiting	2	68	US, RoW	Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta®	Effector Therapeutics, Medpace, Inc., ICON plc	Non-small Cell Lung Cancer	10/24	12/24
FID-007-003, NCT06332092: FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma	Recruiting	2	46	US	FID007, Paclitaxel in Polyethyloxazoline Polymer; FID-007; FID007 (CN); FID 007; Nanoencapsulated Paclitaxel FID-007	Fulgent Pharma LLC.	Head and Neck Squamous Cell Carcinoma	03/25	12/25
NCT03893682: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas	Active, not recruiting	1	160	US	CG-806, Luxeptinib	Aptose Biosciences Inc.	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma	12/24	05/25
NCT06207032: TEMPUS ARIES: A Biobank Registry Platform Study in Oncology	Recruiting	N/A	500	US		Tempus AI	Cancer	06/29	06/29
Carter, Raven
NCT05481151: A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV Feb 2024 - Dec 2024 : Topline data for adults with PV	Active, not recruiting	3	111	Canada, US	P1101 (Ropeginterferon alfa-2b-njft), Ropeginterferon alfa-2b-njft (P1101)	PharmaEssentia	Polycythemia Vera	12/24	07/25
KICKSTART, NCT04622007: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC Jan 2024 - Mar 2024 : Q1'24 - Data from P2b KICKSTARTtrial in combination with Keytruda for PD-L1+ve 1L NSCLC	Active, not recruiting	2	68	US, RoW	Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta®	Effector Therapeutics, Medpace, Inc., ICON plc	Non-small Cell Lung Cancer	10/24	12/24
NCT06207032: TEMPUS ARIES: A Biobank Registry Platform Study in Oncology	Recruiting	N/A	500	US		Tempus AI	Cancer	06/29	06/29